CellCarta Strengthens its Histological Biomarker Franchise by Acquiring Artificial Intelligence-Based Quantitative Pathology Leader Reveal Biosciences

MONTREAL, May 11, 2021 /CNW Telbec/ - CellCarta, a global provider of precision medicine services, announced today the acquisition of Reveal Biosciences ("Reveal"), a San Diego California based computational pathology company offering cutting-edge artificial intelligence (AI)-based quantitative pathology and immunohistochemistry services to the biopharmaceutical industry. This acquisition further strengthens CellCarta's position as a leading provider of histopathology biomarker services and will enable the company to broaden its offering in AI-enabled multi-omic data analysis services and applications.

NewsGuest UserMay 11, 2021CellCarta, artificial intelligence, Reveal Biosciences